寿仙谷（603896）公告，公司全资子公司浙江寿仙谷药房连锁有限公司拟以330万元受让浙江寿仙谷投 资管理有限公司所持有的杭州寿仙谷健康药房连锁有限公司100%股权。本次交易完成后，杭州寿仙谷 药房将成为寿仙谷的全资孙公司。此次交易旨在提高资产完整性，进一步整合优质资源，交易对价以现 金方式支付，并已签署相关协议。 ...

Core Viewpoint - The announcement provides an update on the conversion results of the "Shou 22 Convertible Bond" and the changes in the company's share capital as of March 31, 2025, highlighting the low conversion rate and the remaining unconverted bond amount. Group 1: Conversion Status - From May 23, 2023, to March 31, 2025, the total amount converted from the "Shou 22 Convertible Bond" is 309,000 yuan, accounting for 0.0776% of the total issuance [2][5] - The total number of shares formed from the conversion is 8,097 shares, representing 0.0041% of the company's total shares before conversion [2][5] - As of March 31, 2025, the amount of "Shou 22 Convertible Bond" that has not been converted is 397,691,000 yuan, which constitutes 99.92% of the total issuance [2][6] Group 2: Recent Quarter Conversion - In the first quarter of 2025, from January 1 to March 31, the cumulative conversion amount is 1,000 yuan, which is 0.0003% of the total convertible bond issuance [2][5] - The number of shares formed during this period is 26 shares, accounting for 0.00001% of the total shares before conversion [2][5] Group 3: Bond Issuance Overview - The "Shou 22 Convertible Bond" was approved for issuance on November 17, 2022, with a total issuance of 39.8 million yuan, consisting of 398,000 bonds at a face value of 100 yuan each [3] - The bond has a six-year term with a tiered interest rate starting from 0.5% in the first year to 2.5% in the sixth year [3] Group 4: Conversion Price Adjustments - The initial conversion price was set at 38.08 yuan per share, which was adjusted to 37.65 yuan on July 4, 2023, and further adjusted to 37.27 yuan on June 20, 2024, and finally to 37.11 yuan on July 8, 2024, due to various corporate actions [4]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-013 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于"寿 22 转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、"寿 22 转债"发行上市概况 三、股本变动情况 单位：股 | 股份类别 | 变动前（2024 | | 年 | 本次可转债转股 | 变动后（2025 | | 年 3 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 12 月 日） | 31 | | | 月 31 | 日） | | | 有限售条件流通股 | 0 | | | 0 | 0 | | | | 无限售条件流通股 | 198,243,832 | | | 26 | 198,243,858 | | | | 总股本 | 198,243,832 | | | 26 | 19 ...

本报讯(记者吴文婧)近日，国务院办公厅印发了《关于提升中药质量促进中医药产业高质量发展的意 见》，提出加快构建现代化产业体系，形成传承创新并重、布局结构合理、装备制造先进、质量安全可 靠、竞争能力强的中医药产业高质量发展格局。 浙江寿仙谷（603896）医药股份有限公司(以下简称"寿仙谷"，股票代码"603896")专业从事灵芝、铁皮 石斛、西红花等名贵中药材的品种选育、栽培、加工和销售，公司始终坚守"科技立企"战略，聚焦中药 全产业链关键核心技术的研究与开发，守正创新，攻克了制约我国灵芝、铁皮石斛等优良品种、优质原 料、高质量产品等"卡脖子"难题。 在全球加速迈向数字化时代的当下，数字化转型已成为企业破局突围、实现高质量发展的必由之路，寿 仙谷充分利用云计算、大数据、物联网等新一代信息技术，对生产、管理、销售等各个环节进行全面升 级。通过建立智慧工厂和智能制造管理系统，实现从原材料采购、生产加工、质量检测到产品销售的全 链条数字化管理。 产业协同加速数字生态高效管理 寿仙谷数字化建设是提升制造业企业数字化水平的重要路径，打造数字化工厂的过程，也是驱动业务流 程再造和要素资源重组，以及组织形态重构的过程，在提 ...

Industry Overview - The traditional Chinese medicine and health products market is experiencing significant growth, driven by the "Healthy China" strategy and increasing public health demands. The sales of health food are projected to reach 347.5 billion yuan in 2024 and exceed 360 billion yuan in 2025 [1] - The Chinese herbal health product market is also growing rapidly due to policy support and the revival of traditional medicine [1] Company Profile - Shouxiangu (603896.SH) is a national high-tech enterprise specializing in the breeding, cultivation, processing, and sales of precious Chinese medicinal materials such as Ganoderma lucidum, Dendrobium officinale, and saffron. Its core products include various forms of Ganoderma spore powder and Dendrobium products [1] Research and Development Achievements - Shouxiangu has made significant investments in research and innovation, achieving notable honors in scientific research and major advancements in product diversification. The company was a co-applicant for the National Science and Technology Progress Award for the project focusing on key technology innovation in the full industrial chain of edible fungi [2] - The company has developed 12 new food products in the first half of 2024, including a plant-based beverage and a health capsule that has received domestic health food registration [2] Collaborative Projects - Shouxiangu actively engages in industry-academia-research collaborations, partnering with various academic institutions to develop functional products from medicinal materials. Projects include research on high-value utilization of by-products and mechanisms for immune regulation and anti-tumor effects [3] Market Expansion Strategies - To enhance market presence, Shouxiangu employs a multi-channel approach, utilizing a marketing strategy that combines renowned doctors, medicines, and stores. This has led to increased brand recognition and customer loyalty [4] - The company is expanding its market reach by optimizing its organizational structure and enhancing performance assessments, which has improved team vitality and execution [4] - Online sales efforts are being intensified through various digital platforms, allowing for direct consumer interaction and timely market feedback [4] Future Outlook - With the rising health awareness and demand for high-quality health products, the Chinese herbal health product industry holds substantial growth potential. Shouxiangu aims to leverage its technological foundation, channel layout, and brand influence to deliver more quality health products and promote the industry's development towards high quality and strong innovation [5]

注：1、上表数据以公司未经审计的合并报表数据填列。 二、经营业绩和财务状况情况说明 （一）经营业绩、财务状况及影响经营业绩的主要因素 寿仙谷: 寿仙谷2024年度业绩快报公告 证券代码：603896 证券简称：寿仙谷 公告编号：2025-012 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2024年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以浙江寿仙谷医药股份有限公司（以下简称"公司"）2024年年度 报告中披露的数据为准，敬请投资者注意投资风险。 一、2024年度主要财务数据和指标 | | | | 单位：元 币种：人民币 | | | | | --- | --- | --- | --- | --- | --- | --- | | 项 | 目 | 本报告期 | 上年同期 | | | 增减变动幅度（％） | | 营业总收入 | | 699,107,038.17 | 784,347,256.55 | | -10.87 | ...

Financial Performance - Total revenue for 2024 was CNY 699.11 million, a decrease of 10.87% compared to the previous year[4] - Operating profit for 2024 was CNY 184.03 million, down 27.75% year-on-year[4] - Net profit attributable to shareholders for 2024 was CNY 183.55 million, a decline of 27.87% from the previous year[4] - Net profit excluding non-recurring gains and losses was CNY 152.99 million, down 32.52% year-on-year[4] - Basic earnings per share decreased to CNY 0.93, a drop of 28.46% compared to the previous year[4] - The weighted average return on equity decreased by 4.24 percentage points to 8.20%[4] Assets and Equity - Total assets at the end of the reporting period were CNY 3,139.23 million, a decrease of 1.11% from the previous year[4] - Shareholders' equity attributable to the parent company increased by 6.06% to CNY 2,302.85 million[4] Performance Factors - The decline in performance was attributed to insufficient economic recovery and a lack of timely marketing reforms[7][8] Reporting Notes - The financial data presented are preliminary and subject to change in the final annual report[9]

报告期内，经济回暖不及预期，消费信心不足，高端消费需求收缩；公司营销改革步伐未及时跟上外部 环境变化。 人民财讯3月24日电，寿仙谷(603896)3月24日晚间发布2024年度业绩快报，2024年度实现营业收入6.99 亿元，同比下降10.87%；归属于上市公司股东的净利润1.84亿元，同比下降27.87%；基本每股收益0.93 元。 ...

| 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2025-010 | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 转债 22 | | 浙江寿仙谷医药股份有限公司 关于全资子公司完成国产保健食品备案的公告 | 产品名称 | 寿仙山牌破壁灵芝孢子粉片 | | --- | --- | | 保健功能 | 有助于增强免疫力 | | 备案号 | 食健备 G202533000784 | | 备案人 | 金华寿仙谷药业有限公司 | | 备案人地址 | 浙江省金华市武义县壶山街道商城路 10 号 | | 备案结论 | 按照《中华人民共和国食品安全法》《保健食品注册与备 | | | 案管理办法》等法律、规章的规定，予以备案。 | 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一 步补充完善公司的产品品类，丰富公司的产品线，提升公司在保健食品领域的竞 争力，符合公司布局大健康产业的战略规划，为企业持续发展打下扩容基础。 特此公告。 浙江寿仙谷医药股份有限公司董事会 2025 年 3 月 19 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...

| 证券代码：603896 | 证券简称：寿仙谷 公告编号：2025-009 | | --- | --- | | 债券代码：113660 | 债券简称：寿 22 转债 | 二、募集资金管理情况 1、"寿仙转债"募集资金管理情况 浙江寿仙谷医药股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 1、"寿仙转债"募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可[2020]658 号文核准，浙江寿仙谷医药股份有限公司（以下简称"公司"）已公开发行总额 为人民币 36,000 万元可转换公司债券，每张面值 100 元人民币，共 3,600,000 张， 期限为 6 年。此次公开发行可转换公司债券募集资金总额扣除保荐承销费用、律 师、会计师、资信评级、信息披露及发行手续费等发行费用后净额为人民币 349,155,660.38 元。上述募集资金已经全部存放于募集资金专户管理，立信会计 师事务所（特殊普通合伙）已就募集资金到位情况进行了审验并出具 ...